Physician profile
Daniel Barlow
NPI 1457738338
$2,513.69
in general payments reported to CMS, 2019-2025
29 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.49 · 2021: $154 · 2022: $149 · 2023: $372 · 2024: $191 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.14 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $261.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $250.25 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $227.52 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $130.85 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $124.26 | 2025 | |
| Abbott Laboratories | $113.17 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Ardelyx, INC. | $84.78 | 2025 | Ibsrela |
| Lilly USA, LLC | $81.66 | 2024-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $79.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $76.62 | 2021-2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $75.12 | 2025 | Fanapt |
| Amgen INC. | $64.82 | 2021-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.36 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.95 | 2023-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $53.04 | 2025 | Austedo Xr |
| Edwards Lifesciences Corporation | $43.75 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $39.35 | 2023-2024 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.41 | 2025 | Rexulti |
| Corcept Therapeutics | $33.25 | 2025 | Korlym |
| Radius Health, INC. | $31.79 | 2025 | Tymlos |
| Astellas Pharma US INC | $25.15 | 2025 | Veozah |
| Tris Pharma INC | $23.60 | 2025 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $18.91 | 2025 | Inspire |
| Boston Scientific Corporation | $15.26 | 2022 | |
| Daiichi Sankyo INC. | $14.61 | 2025 | Injectafer |
| Supernus Pharmaceuticals, INC. | $14.26 | 2021 | |
| Philips North America LLC | $14.15 | 2023 | |
| Eisai INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.